PDCD1 and hepatocellular carcinoma: Treatment options for advanced HCC include antiangiogenic therapies (e.g., tyrosine kinase inhibitors [TKIs] and monoclonal antibodies) and immune checkpoint inhibitors [ICIs] (anti-programmed cell death protein-1 [anti-PD-1], anti-programmed death-ligand [PD-L1] and cytotoxic T-lymphocyte associated protein-4 [CTLA-4] inhibitors) [9].